Navigation Links
Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences
Date:6/8/2015

SAN DIEGO, June 8, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.

"We continue to advance our clinical programs and present data to the medical community demonstrating the advantages of using our urine-based molecular diagnostics in the management of various cancer types," stated Mark Erlander, Ph.D., chief scientific officer of Trovagene. "The data sets to be presented at these conferences support the clinical utility of our non-invasive cancer monitoring tests in both lung and colorectal cancers, and their ability to empower oncologists to detect and quantitatively track driver mutations to improve treatment decisions."

2015 Cancer Markers and Liquid Biopsies June 11 2015, 11:25 a.m. PDT Oral Presentation
Early Pharmacodynamics Using Urinary ctDNA as a Putative Biomarker of Drug Response
Presenter: Mark Erlander, Ph.D., Trovagene, Inc.
Highlights: High frequency testing of circulating tumor (ct)DNA mutations in patients receiving molecularly targeted therapies can be used to determine early changes in mutation load brought about by treatment administration, in addition to tumor dynamics when used to monitor treatment response longitudinally

June 12 2015, 10:45 a.m. PDT Oral Presentation
Monitoring Urinary Circulating Tumor DNA (ctDNA) KRAS for Treatment Response in Patients with Metastatic Colorectal Cancer (mCRC)
Collaborator: Afsaneh Barzi, M.D., USC Norris Comprehensive Cancer Center
Highlights: Potential to guide treatment decisions in metastatic colorectal cancer (mCRC) patients based on ctDNA KRAS mutation dynamics

AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy June 15, 2015, 12:30 – 3:00 p.m. CDT Poster Session
Quantitative Monitoring of EGFR Mutations in Urinary Circulating Tumor DNA Enables Non-Invasive Pharmacodynamic Assessment of Anti-EGFR Drug Response
Single Cell and Circulating Free Nucleic Acid Sequencing Session, Abstract: # 29
Collaborator: Hatim Husain, M.D., UCSD Moores Cancer Center
Highlights:  

  • Urine-based EGFR ctDNA assay has been shown to outperform tissue biopsy for the detection of EGFR T790M mutations in metastatic lung cancer patients
  • Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy, and months before detection of cancer progression with imaging
  • Tracking ctDNA in urine enables determination of response to next generation EGFR T790M inhibitors within days of initial treatment
  • About Trovagene, Inc.

    Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

    ContactInvestor RelationsMedia RelationsDavid Moskowitz and Amy Caterina

    Investor RelationsIan Stone

    Account DirectorTrovagene, Inc.Canale Communications, Inc.858-952-7593619-849-5388ir@trovagene.comian@canalecomm.com Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

     


    '/>"/>
    SOURCE Trovagene, Inc.
    Copyright©2015 PR Newswire.
    All rights reserved

    Related biology news :

    1. Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast
    2. Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Centers Clinical Research Division
    3. Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea
    4. Experts provide much-needed policy analysis for clinical integration of next generation sequencing
    5. Sponsors And CROs Rapidly Adopting MedNet Solutions eClinical Technology Platform
    6. Clinical trial tests COXEN model to predict best treatment for bladder cancer
    7. New Clinical Informatics Curriculum Prepares Future Pathologists
    8. Damon Runyon Cancer Research foundation awards $4M to 10 top young clinical investigators
    9. Broccoli sprout drink enhances detoxification of air pollutants in clinical trial in China
    10. ESMO survey sheds light on common clinical practice for incompletely resected lung cancer
    11. Quadrapeutics works in preclinical study of hard-to-treat tumors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2018)... (PRWEB) , ... August 01, 2018 , ... Dr. Asher ... announced the winning recipients of the 2018 IAC Awards at the 23rd World Congress ... the committee also named four faculty to receive the Distinguished Fellowship Awards. , Dr. ...
    (Date:7/31/2018)... ... , ... ACEA Biosciences, is a privately owned biotechnology company which develops cutting ... RTCA S16, which the ideal entry level model for exploratory studies in cell biology. ... in any standard CO2 tissue culture incubator. The user friendly RTCA software allows ...
    (Date:7/29/2018)... , ... July 29, 2018 , ... Dr. William Plikerd, ... energy treated nutraceutical to improve overall immunity and to combat inflammation and autoimmune disorders. ... as inflammation. The following data was reported:, Up to ...
    Breaking Biology News(10 mins):
    (Date:7/25/2018)... (PRWEB) , ... July 25, 2018 , ... ... vivo research utilizing its state-of-the-art Digital Vivarium™ and Vium Cloud approach to accelerate ... to Chief Scientific Officer. Additionally, the company announced the appointment of Jeff Caron ...
    (Date:7/25/2018)... ... July 25, 2018 , ... Almac Clinical ... and supplies data through its flagship IXRS® 3 Interactive Response Technology (IRT) ... This podcast features both Almac thought leaders and outside experts discussing best practices ...
    (Date:7/24/2018)... OMAHA, Neb. (PRWEB) , ... July 23, 2018 ... ... the impact of a biofield energy treated nutraceutical to increase immunity and improve ... well as, immune function response assessed in the preclinical research were significantly reduced. ...
    (Date:7/24/2018)... ... , ... Boval was founded in 1978 when Mr. Douglas Northcott began making ... days most of the BSA manufactured was for blood banking reagents; however, in the ... cards changed that market and displaced most of the large volume needs. Boval ...
    Breaking Biology Technology: